Predict your next investment

HEALTHCARE | Drug Development
excelimmune.com

See what CB Insights has to offer

Stage

Series C | Alive

Total Raised

$28.24M

Last Raised

$12M | 10 yrs ago

About Excelimmune

Excelimmune is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. This next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens.

Excelimmune Headquarter Location

519 Somerville Avenue PMB 214

Woburn, Massachusetts, 02143,

United States

Latest Excelimmune News

Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies

Jul 7, 2015

Catalent, Inc. to Present at Two Investor Conferences in May Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has signed an exclusive licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) technology platform. The platform has the potential to enable a consistent and cost-effective method to manufacture multiple recombinant antibodies or other recombinant proteins in a single batch culture. Under the licensing agreement, Catalent will continue development work on the platform, both internally and in conjunction with partner-sponsored programs. Catalent will also be able to leverage its own proprietary GPEx® technology to help enable that development. “Combination antibody therapies are becoming the treatment standard for many indications within oncology, immuno-oncology, and infectious diseases,” commented Mike Riley, Vice President/General Manager, Catalent Biologics. He added, “This technology platform has the potential to allow production of multiple antibodies in a significantly more cost-effective manner. This can allow innovators to look to combinations earlier in clinical development, and could be the difference in a new treatment getting to patients.” Excelimmune's antibody combination expression system is based on a key innovation: the use of stable pools of cells generated by multiple directed gene insertions, instead of clonal cell lines. This attribute contributes to a quick, stable, and flexible culture system for mixtures of cells producing different antibodies. This technology has the potential to pave the way for more consistent, cost-effective production of antibody combinations, which will allow complex antibody therapeutics to gain greater accessibility to the clinic. About Catalent Catalent, Inc. is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,600 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com More products. Better treatments. Reliably supplied.™ For the original version on PRWeb visit: http://www.prweb.com/releases/2015/07/prweb12833303.htm

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Excelimmune

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Excelimmune is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Excelimmune Patents

Excelimmune has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/26/2013

9/20/2016

Molecular biology, Immunology, Clusters of differentiation, Immune system, Transcription factors

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/26/2013

00/00/0000

00/00/0000

Grant Date

9/20/2016

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Immunology, Clusters of differentiation, Immune system, Transcription factors

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Excelimmune Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Excelimmune Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.